|
|
|
|
|
|
|
|
|
|
|
|
|
<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 19, 1996
-----------------
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
North Carolina
- --------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
0-20183 56-1640186
- ------------------------- -----------------------------
(Commission file Number) (IRS Employer ID Number)
115 North Third Street, 5th Floor, Wilmington, North Carolina 28401
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (910) 251-0081
-----------------------------
N/A
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE> 2
Item 5. Other Events.
The Registrant is filing this Current Report on Form 8-K, at its
option, to report its results of operations for the month ended October 31,
1996, in order to publish financial results covering at least 30 days of
post-merger combined operations of the Registrant and Applied Bioscience
International Inc., which it acquired effective September 26, 1996.
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC., AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENT OF OPERATIONS
(unaudited)
(in thousands, except per share amounts)
<TABLE>
<CAPTION>
One Month Ended
October 31, 1996
----------------
<S> <C>
Life sciences revenues, net of reimbursed
costs of $4,181 $13,519
Environmental sciences revenues, net of
reimbursed costs of $373 4,145
-------
17,664
-------
Direct costs - Life sciences 7,088
Direct costs - Environmental sciences 2,848
Selling, general and administrative expenses 5,347
Depreciation and amortization 917
-------
16,200
-------
Income from operations 1,464
Other income, net 185
-------
Income before provision for income taxes 1,649
Provision for income taxes 655
-------
Net income $ 994
=======
Net income per share $ 0.05
=======
Weighted average number of common
shares outstanding 21,575
=======
</TABLE>
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
Date: November 19, 1996 /s/ RUDY C. HOWARD
------------------------------------------------
Rudy C. Howard,
Chief Financial Officer, Vice President
Finance, Secretary and Treasurer
(Principal Financial and Accounting
Officer)
|
|